Dopamine and Opioid Neurotransmission in Behavioral Addictions: A Comparative PET Study in Pathological Gambling and Binge Eating

Although behavioral addictions share many clinical features with drug addictions, they show strikingly large variation in their behavioral phenotypes (such as in uncontrollable gambling or eating). Neurotransmitter function in behavioral addictions is poorly understood, but has important implication...

Full description

Saved in:
Bibliographic Details
Published inNeuropsychopharmacology (New York, N.Y.) Vol. 42; no. 5; pp. 1169 - 1177
Main Authors Majuri, Joonas, Joutsa, Juho, Johansson, Jarkko, Voon, Valerie, Alakurtti, Kati, Parkkola, Riitta, Lahti, Tuuli, Alho, Hannu, Hirvonen, Jussi, Arponen, Eveliina, Forsback, Sarita, Kaasinen, Valtteri
Format Journal Article
LanguageEnglish
Published England Nature Publishing Group 01.04.2017
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Although behavioral addictions share many clinical features with drug addictions, they show strikingly large variation in their behavioral phenotypes (such as in uncontrollable gambling or eating). Neurotransmitter function in behavioral addictions is poorly understood, but has important implications in understanding its relationship with substance use disorders and underlying mechanisms of therapeutic efficacy. Here, we compare opioid and dopamine function between two behavioral addiction phenotypes: pathological gambling (PG) and binge eating disorder (BED). Thirty-nine participants (15 PG, 7 BED, and 17 controls) were scanned with [ C]carfentanil and [ F]fluorodopa positron emission tomography using a high-resolution scanner. Binding potentials relative to non-displaceable binding (BP ) for [ C]carfentanil and influx rate constant (K ) values for [ F]fluorodopa were analyzed with region-of-interest and whole-brain voxel-by-voxel analyses. BED subjects showed widespread reductions in [ C]carfentanil BP in multiple subcortical and cortical brain regions and in striatal [ F]fluorodopa K compared with controls. In PG patients, [ C]carfentanil BP was reduced in the anterior cingulate with no differences in [ F]fluorodopa K compared with controls. In the nucleus accumbens, a key region involved in reward processing, [ C]Carfentanil BP was 30-34% lower and [ F]fluorodopa K was 20% lower in BED compared with PG and controls (p<0.002). BED and PG are thus dissociable as a function of dopaminergic and opioidergic neurotransmission. Compared with PG, BED patients show widespread losses of mu-opioid receptor availability together with presynaptic dopaminergic defects. These findings highlight the heterogeneity underlying the subtypes of addiction and indicate differential mechanisms in the expression of pathological behaviors and responses to treatment.
AbstractList Although behavioral addictions share many clinical features with drug addictions, they show strikingly large variation in their behavioral phenotypes (such as in uncontrollable gambling or eating). Neurotransmitter function in behavioral addictions is poorly understood, but has important implications in understanding its relationship with substance use disorders and underlying mechanisms of therapeutic efficacy. Here, we compare opioid and dopamine function between two behavioral addiction phenotypes: pathological gambling (PG) and binge eating disorder (BED). Thirty-nine participants (15 PG, 7 BED, and 17 controls) were scanned with [ 11 C]carfentanil and [ 18 F]fluorodopa positron emission tomography using a high-resolution scanner. Binding potentials relative to non-displaceable binding (BP ND ) for [ 11 C]carfentanil and influx rate constant ( K i ) values for [ 18 F]fluorodopa were analyzed with region-of-interest and whole-brain voxel-by-voxel analyses. BED subjects showed widespread reductions in [ 11 C]carfentanil BP ND in multiple subcortical and cortical brain regions and in striatal [ 18 F]fluorodopa K i compared with controls. In PG patients, [ 11 C]carfentanil BP ND was reduced in the anterior cingulate with no differences in [ 18 F]fluorodopa K i compared with controls. In the nucleus accumbens, a key region involved in reward processing, [ 11 C]Carfentanil BP ND was 30–34% lower and [ 18 F]fluorodopa K i was 20% lower in BED compared with PG and controls ( p <0.002). BED and PG are thus dissociable as a function of dopaminergic and opioidergic neurotransmission. Compared with PG, BED patients show widespread losses of mu-opioid receptor availability together with presynaptic dopaminergic defects. These findings highlight the heterogeneity underlying the subtypes of addiction and indicate differential mechanisms in the expression of pathological behaviors and responses to treatment.
Although behavioral addictions share many clinical features with drug addictions, they show strikingly large variation in their behavioral phenotypes (such as in uncontrollable gambling or eating). Neurotransmitter function in behavioral addictions is poorly understood, but has important implications in understanding its relationship with substance use disorders and underlying mechanisms of therapeutic efficacy. Here, we compare opioid and dopamine function between two behavioral addiction phenotypes: pathological gambling (PG) and binge eating disorder (BED). Thirty-nine participants (15 PG, 7 BED, and 17 controls) were scanned with [ C]carfentanil and [ F]fluorodopa positron emission tomography using a high-resolution scanner. Binding potentials relative to non-displaceable binding (BP ) for [ C]carfentanil and influx rate constant (K ) values for [ F]fluorodopa were analyzed with region-of-interest and whole-brain voxel-by-voxel analyses. BED subjects showed widespread reductions in [ C]carfentanil BP in multiple subcortical and cortical brain regions and in striatal [ F]fluorodopa K compared with controls. In PG patients, [ C]carfentanil BP was reduced in the anterior cingulate with no differences in [ F]fluorodopa K compared with controls. In the nucleus accumbens, a key region involved in reward processing, [ C]Carfentanil BP was 30-34% lower and [ F]fluorodopa K was 20% lower in BED compared with PG and controls (p<0.002). BED and PG are thus dissociable as a function of dopaminergic and opioidergic neurotransmission. Compared with PG, BED patients show widespread losses of mu-opioid receptor availability together with presynaptic dopaminergic defects. These findings highlight the heterogeneity underlying the subtypes of addiction and indicate differential mechanisms in the expression of pathological behaviors and responses to treatment.
Although behavioral addictions share many clinical features with drug addictions, they show strikingly large variation in their behavioral phenotypes (such as in uncontrollable gambling or eating). Neurotransmitter function in behavioral addictions is poorly understood, but has important implications in understanding its relationship with substance use disorders and underlying mechanisms of therapeutic efficacy. Here, we compare opioid and dopamine function between two behavioral addiction phenotypes: pathological gambling (PG) and binge eating disorder (BED). Thirty-nine participants (15 PG, 7 BED, and 17 controls) were scanned with [ super(11)C]carfentanil and [ super(18)F]fluorodopa positron emission tomography using a high-resolution scanner. Binding potentials relative to non-displaceable binding (BP sub(ND)) for [ super(11)C]carfentanil and influx rate constant (K sub(i)) values for [ super(18)F]fluorodopa were analyzed with region-of-interest and whole-brain voxel-by-voxel analyses. BED subjects showed widespread reductions in [ super(11)C]carfentanil BP sub(ND) in multiple subcortical and cortical brain regions and in striatal [ super(18)F]fluorodopa K sub(i) compared with controls. In PG patients, [ super(11)C]carfentanil BP sub(ND) was reduced in the anterior cingulate with no differences in [ super(18)F]fluorodopa K sub(i) compared with controls. In the nucleus accumbens, a key region involved in reward processing, [ super(11)C]Carfentanil BP sub(ND) was 30-34% lower and [ super(18)F]fluorodopa K sub(i) was 20% lower in BED compared with PG and controls (p<0.002). BED and PG are thus dissociable as a function of dopaminergic and opioidergic neurotransmission. Compared with PG, BED patients show widespread losses of mu-opioid receptor availability together with presynaptic dopaminergic defects. These findings highlight the heterogeneity underlying the subtypes of addiction and indicate differential mechanisms in the expression of pathological behaviors and responses to treatment.
Although behavioral addictions share many clinical features with drug addictions, they show strikingly large variation in their behavioral phenotypes (such as in uncontrollable gambling or eating). Neurotransmitter function in behavioral addictions is poorly understood, but has important implications in understanding its relationship with substance use disorders and underlying mechanisms of therapeutic efficacy. Here, we compare opioid and dopamine function between two behavioral addiction phenotypes: pathological gambling (PG) and binge eating disorder (BED). Thirty-nine participants (15 PG, 7 BED, and 17 controls) were scanned with [11 C]carfentanil and [18 F]fluorodopa positron emission tomography using a high-resolution scanner. Binding potentials relative to non-displaceable binding (BPND ) for [11 C]carfentanil and influx rate constant (Ki ) values for [18 F]fluorodopa were analyzed with region-of-interest and whole-brain voxel-by-voxel analyses. BED subjects showed widespread reductions in [11 C]carfentanil BPND in multiple subcortical and cortical brain regions and in striatal [18 F]fluorodopa Ki compared with controls. In PG patients, [11 C]carfentanil BPND was reduced in the anterior cingulate with no differences in [18 F]fluorodopa Ki compared with controls. In the nucleus accumbens, a key region involved in reward processing, [11 C]Carfentanil BPND was 30-34% lower and [18 F]fluorodopa Ki was 20% lower in BED compared with PG and controls (p<0.002). BED and PG are thus dissociable as a function of dopaminergic and opioidergic neurotransmission. Compared with PG, BED patients show widespread losses of mu-opioid receptor availability together with presynaptic dopaminergic defects. These findings highlight the heterogeneity underlying the subtypes of addiction and indicate differential mechanisms in the expression of pathological behaviors and responses to treatment.
Although behavioral addictions share many clinical features with drug addictions, they show strikingly large variation in their behavioral phenotypes (such as in uncontrollable gambling or eating). Neurotransmitter function in behavioral addictions is poorly understood, but has important implications in understanding its relationship with substance use disorders and underlying mechanisms of therapeutic efficacy. Here, we compare opioid and dopamine function between two behavioral addiction phenotypes: pathological gambling (PG) and binge eating disorder (BED). Thirty-nine participants (15 PG, 7 BED, and 17 controls) were scanned with [11C]carfentanil and [18F]fluorodopa positron emission tomography using a high-resolution scanner. Binding potentials relative to non-displaceable binding (BPND) for [11C]carfentanil and influx rate constant (Ki) values for [18F]fluorodopa were analyzed with region-of-interest and whole-brain voxel-by-voxel analyses. BED subjects showed widespread reductions in [11C]carfentanil BPND in multiple subcortical and cortical brain regions and in striatal [18F]fluorodopa Ki compared with controls. In PG patients, [11C]carfentanil BPND was reduced in the anterior cingulate with no differences in [18F]fluorodopa Ki compared with controls. In the nucleus accumbens, a key region involved in reward processing, [11C]Carfentanil BPND was 30-34% lower and [18F]fluorodopa Ki was 20% lower in BED compared with PG and controls (p<0.002). BED and PG are thus dissociable as a function of dopaminergic and opioidergic neurotransmission. Compared with PG, BED patients show widespread losses of mu-opioid receptor availability together with presynaptic dopaminergic defects. These findings highlight the heterogeneity underlying the subtypes of addiction and indicate differential mechanisms in the expression of pathological behaviors and responses to treatment.Although behavioral addictions share many clinical features with drug addictions, they show strikingly large variation in their behavioral phenotypes (such as in uncontrollable gambling or eating). Neurotransmitter function in behavioral addictions is poorly understood, but has important implications in understanding its relationship with substance use disorders and underlying mechanisms of therapeutic efficacy. Here, we compare opioid and dopamine function between two behavioral addiction phenotypes: pathological gambling (PG) and binge eating disorder (BED). Thirty-nine participants (15 PG, 7 BED, and 17 controls) were scanned with [11C]carfentanil and [18F]fluorodopa positron emission tomography using a high-resolution scanner. Binding potentials relative to non-displaceable binding (BPND) for [11C]carfentanil and influx rate constant (Ki) values for [18F]fluorodopa were analyzed with region-of-interest and whole-brain voxel-by-voxel analyses. BED subjects showed widespread reductions in [11C]carfentanil BPND in multiple subcortical and cortical brain regions and in striatal [18F]fluorodopa Ki compared with controls. In PG patients, [11C]carfentanil BPND was reduced in the anterior cingulate with no differences in [18F]fluorodopa Ki compared with controls. In the nucleus accumbens, a key region involved in reward processing, [11C]Carfentanil BPND was 30-34% lower and [18F]fluorodopa Ki was 20% lower in BED compared with PG and controls (p<0.002). BED and PG are thus dissociable as a function of dopaminergic and opioidergic neurotransmission. Compared with PG, BED patients show widespread losses of mu-opioid receptor availability together with presynaptic dopaminergic defects. These findings highlight the heterogeneity underlying the subtypes of addiction and indicate differential mechanisms in the expression of pathological behaviors and responses to treatment.
Author Parkkola, Riitta
Voon, Valerie
Hirvonen, Jussi
Majuri, Joonas
Arponen, Eveliina
Kaasinen, Valtteri
Alho, Hannu
Lahti, Tuuli
Joutsa, Juho
Johansson, Jarkko
Alakurtti, Kati
Forsback, Sarita
Author_xml – sequence: 1
  givenname: Joonas
  surname: Majuri
  fullname: Majuri, Joonas
– sequence: 2
  givenname: Juho
  surname: Joutsa
  fullname: Joutsa, Juho
– sequence: 3
  givenname: Jarkko
  surname: Johansson
  fullname: Johansson, Jarkko
– sequence: 4
  givenname: Valerie
  surname: Voon
  fullname: Voon, Valerie
– sequence: 5
  givenname: Kati
  surname: Alakurtti
  fullname: Alakurtti, Kati
– sequence: 6
  givenname: Riitta
  surname: Parkkola
  fullname: Parkkola, Riitta
– sequence: 7
  givenname: Tuuli
  surname: Lahti
  fullname: Lahti, Tuuli
– sequence: 8
  givenname: Hannu
  surname: Alho
  fullname: Alho, Hannu
– sequence: 9
  givenname: Jussi
  surname: Hirvonen
  fullname: Hirvonen, Jussi
– sequence: 10
  givenname: Eveliina
  surname: Arponen
  fullname: Arponen, Eveliina
– sequence: 11
  givenname: Sarita
  surname: Forsback
  fullname: Forsback, Sarita
– sequence: 12
  givenname: Valtteri
  surname: Kaasinen
  fullname: Kaasinen, Valtteri
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27882998$$D View this record in MEDLINE/PubMed
BookMark eNqNkkFv1DAQhS1URLeFG2dkiQsHstixEzscKm2XpSBVtBJF6s2a2N5dV4kd7GSlHvnneGmpoOLAyZb9vZl5M3OEDnzwFqGXlMwpYfKdH4Z5SWg9L-vqCZpRwUlRM359gGZENqygjF0foqOUbgihlajlM3RYCinLppEz9ONDGKB33mLwBl8MLjiDv9gphjGCT71LyQWPncendgs7FyJ0eGGM02N-T-_xAi9DP0CE0e0svlxd4a_jZG73iksYt6ELG6ez5gz6tnN-8yvPab5YvMoav3mOnq6hS_bF_XmMvn1cXS0_FecXZ5-Xi_NCc16NBbQtI0xTzVjNoBXctppQrQlISUz2zltjm8qKtTassdxUQGpoGDPrmhsN7Bid3MUdpra3RlufHXZqiK6HeKsCOPX3j3dbtQk7VbFKkIrmAG_uA8TwfbJpVLk72nYdeBumpKiUVNSESv4fKGdNLYRkGX39CL0JU_S5E5kSgjVVSfbUqz-Lf6j69yAz8PYO0DGkFO36AaFE7fdE5T1R-z1RuVcZLx_h2o2wH2m27rp_i34CbhTDLA
CODEN NEROEW
CitedBy_id crossref_primary_10_1038_s41386_019_0368_x
crossref_primary_10_1038_s41467_018_03848_y
crossref_primary_10_1159_000527095
crossref_primary_10_1016_j_neubiorev_2020_11_027
crossref_primary_10_1016_S0985_0562_24_00007_4
crossref_primary_10_1016_j_addbeh_2021_107127
crossref_primary_10_1007_s00259_019_04459_5
crossref_primary_10_1016_j_neuroimage_2020_116922
crossref_primary_10_1016_j_nicl_2023_103315
crossref_primary_10_1007_s10899_021_10100_8
crossref_primary_10_1093_brain_awz010
crossref_primary_10_3390_jpm12101719
crossref_primary_10_1016_j_biopsych_2017_06_010
crossref_primary_10_1016_j_celrep_2023_113630
crossref_primary_10_1111_adb_13264
crossref_primary_10_5817_CP2023_5_6
crossref_primary_10_1038_s41380_018_0230_2
crossref_primary_10_1523_JNEUROSCI_1607_20_2021
crossref_primary_10_3389_fpsyt_2020_559966
crossref_primary_10_1007_s11920_024_01534_z
crossref_primary_10_1192_j_eurpsy_2023_2458
crossref_primary_10_1007_s40429_019_00256_0
crossref_primary_10_1016_j_jns_2020_116952
crossref_primary_10_1016_j_isci_2021_102497
crossref_primary_10_1371_journal_pcbi_1008410
crossref_primary_10_3390_ijms24119574
crossref_primary_10_1093_brain_awz007
crossref_primary_10_3389_fnins_2020_597524
crossref_primary_10_1038_s41366_021_00996_y
crossref_primary_10_1038_s41531_021_00253_z
crossref_primary_10_1097_YCO_0000000000000895
crossref_primary_10_1016_j_pnpbp_2019_109847
crossref_primary_10_1097_PR9_0000000000000769
crossref_primary_10_1016_j_neubiorev_2020_09_034
crossref_primary_10_1016_j_neuroimage_2018_07_069
crossref_primary_10_1038_s41398_021_01559_5
crossref_primary_10_1097_FBP_0000000000000496
crossref_primary_10_1007_s10899_019_09828_1
crossref_primary_10_1007_s40429_019_00240_8
crossref_primary_10_1016_j_pharmthera_2017_08_002
crossref_primary_10_1038_s41598_019_53430_9
crossref_primary_10_1111_adb_12677
crossref_primary_10_3390_molecules27092863
crossref_primary_10_1097_FBP_0000000000000606
crossref_primary_10_1038_s41398_020_0762_5
crossref_primary_10_1038_s41398_024_03088_3
crossref_primary_10_1038_s41583_018_0028_x
crossref_primary_10_1007_s11064_017_2336_3
crossref_primary_10_47482_acmr_1608775
crossref_primary_10_1016_j_pscychresns_2018_03_006
crossref_primary_10_1017_S0033291720005450
crossref_primary_10_1186_s40337_022_00531_y
crossref_primary_10_1515_revneuro_2018_0037
crossref_primary_10_1097_CXA_0000000000000107
crossref_primary_10_3389_fnmol_2019_00255
crossref_primary_10_1016_j_jpsychores_2025_112047
crossref_primary_10_1002_eat_23776
crossref_primary_10_1016_j_euroneuro_2017_09_007
crossref_primary_10_1016_j_biopsych_2018_04_011
crossref_primary_10_1002_mds_27519
crossref_primary_10_1016_j_molmed_2017_12_004
crossref_primary_10_1177_09593543211021157
crossref_primary_10_1080_10550887_2021_1926881
Cites_doi 10.1016/S0006-3223(01)01079-4
10.1038/mp.2014.58
10.1088/0031-9155/52/5/019
10.1038/mp.2015.153
10.1017/S1092852915000681
10.1006/nimg.1997.0303
10.1038/npp.2015.340
10.1017/S1092852915000668
10.1038/jcbfm.1985.87
10.1523/JNEUROSCI.5447-07.2008
10.1038/npp.2014.87
10.4088/JCP.v69n0511
10.3109/00952990.2010.491884
10.1097/00004728-199801000-00027
10.1016/S0893-133X(97)00089-4
10.1016/j.biopsych.2012.11.020
10.1002/14651858.CD001867.pub3
10.1001/archpsyc.62.9.1015
10.1111/add.12066
10.1001/archpsyc.62.1.57
10.1016/j.coph.2008.12.014
10.1016/j.conb.2014.09.005
10.1038/oby.2011.27
10.1038/mp.2013.163
10.1038/npp.2016.12
10.1016/j.biopsych.2012.10.022
10.1055/s-0032-1331747
10.1001/jamapsychiatry.2014.2162
10.1017/S0033291708002900
10.1016/S0896-6273(02)00569-X
10.1038/mp.2012.154
10.1007/s00259-008-0935-6
10.1097/HRP.0000000000000051
10.1002/jlcr.1599
10.1038/npp.2009.129
10.1016/j.neuroimage.2012.02.006
10.1080/10550490902787007
10.1038/jcbfm.2015.53
10.2967/jnumed.111.095240
10.1016/j.neuroimage.2012.06.067
10.7326/M15-2455
10.1111/add.12946
10.1176/appi.ajp.163.2.303
10.1016/j.neuroimage.2006.01.021
10.1159/000435876
10.1001/archneurol.2010.65
10.1002/eat.22114
10.1038/nrn3104
10.1016/j.pscychresns.2012.04.012
10.1192/bjp.bp.110.078105
ContentType Journal Article
Copyright Copyright Nature Publishing Group Apr 2017
Copyright © 2017 American College of Neuropsychopharmacology 2017 American College of Neuropsychopharmacology
Copyright_xml – notice: Copyright Nature Publishing Group Apr 2017
– notice: Copyright © 2017 American College of Neuropsychopharmacology 2017 American College of Neuropsychopharmacology
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TK
7X7
7XB
88E
88G
8AO
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2M
M7P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
7X8
5PM
DOI 10.1038/npp.2016.265
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Psychology Database (Alumni)
ProQuest Pharma Collection
ProQuest SciTech Collection
ProQuest Natural Science Journals
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Psychology Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Psychology
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Psychology Journals (Alumni)
Biological Science Database
ProQuest SciTech Collection
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest Psychology Journals
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
Neurosciences Abstracts
ProQuest One Psychology
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Neurobiology of behavioral addictions
EISSN 1740-634X
EndPage 1177
ExternalDocumentID PMC5357051
4320726611
27882998
10_1038_npp_2016_265
Genre Journal Article
GrantInformation_xml – fundername: Wellcome Trust
  grantid: 093705
– fundername: Medical Research Council
  grantid: MR/P008747/1
GroupedDBID ---
-DZ
-Q-
0R~
29N
2WC
36B
39C
4.4
406
5RE
70F
7X7
88E
8AO
8FI
8FJ
8R4
8R5
AACDK
AANZL
AASML
AATNV
AAYXX
AAYZH
ABAKF
ABBRH
ABDBE
ABFSG
ABIVO
ABJNI
ABLJU
ABUWG
ABZZP
ACAOD
ACGFO
ACGFS
ACKTT
ACMFV
ACMJI
ACPRK
ACRQY
ACSTC
ACZOJ
ADBBV
ADFRT
AEFQL
AEJRE
AEMSY
AENEX
AESKC
AEVLU
AEXYK
AEZWR
AFBBN
AFDZB
AFHIU
AFKRA
AFRAH
AFSHS
AGAYW
AGHAI
AGQEE
AHMBA
AHSBF
AHWEU
AIGIU
AILAN
AIXLP
AJRNO
ALFFA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMYLF
AOIJS
ASPBG
ATHPR
AVWKF
AYFIA
AZFZN
AZQEC
BAWUL
BBNVY
BENPR
BHPHI
BPHCQ
BVXVI
CCPQU
CITATION
CS3
DIK
DNIVK
DPUIP
DWQXO
E3Z
EBLON
EBS
EE.
EIOEI
EJD
F5P
FDB
FDQFY
FERAY
FIGPU
FIZPM
FSGXE
FYUFA
GNUQQ
GX1
HCIFZ
HMCUK
HYE
HZ~
IWAJR
JSO
JZLTJ
KQ8
M1P
M2M
M7P
NQJWS
O9-
OK1
P2P
P6G
PHGZM
PHGZT
PQQKQ
PROAC
PSQYO
PSYQQ
Q2X
RNT
RNTTT
ROL
RPM
SNX
SNYQT
SOHCF
SOJ
SRMVM
SWTZT
TAOOD
TBHMF
TDRGL
TR2
UKHRP
W2D
ZGI
--K
1B1
53G
5VS
AAEDT
AALRI
AAQFI
AAQXK
AAXUO
ABMAC
ABRTQ
ABWVN
ACIUM
ACRPL
ACVFH
ADCNI
ADMUD
ADNMO
AEUPX
AFPUW
AGQPQ
CAG
CGR
COF
CUY
CVF
ECM
EIF
EMB
EMOBN
FEDTE
FGOYB
HVGLF
IHE
LGEZI
LOTEE
M41
MK0
NADUK
NPM
NQ-
NXXTH
PJZUB
PPXIY
PQGLB
R2-
RIG
RNS
RPZ
SEW
SSZ
SV3
ZKB
3V.
7TK
7XB
8FE
8FH
8FK
K9.
LK8
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
ID FETCH-LOGICAL-c445t-abb303c1c3363ab74ebc01cc0a880d2654bde95e7fcd39e4d5a06a933df64dca3
IEDL.DBID 7X7
ISSN 0893-133X
1740-634X
IngestDate Thu Aug 21 17:33:22 EDT 2025
Mon Jul 21 11:44:18 EDT 2025
Fri Jul 11 09:55:05 EDT 2025
Fri Jul 25 08:57:00 EDT 2025
Mon Jul 21 06:01:42 EDT 2025
Thu Apr 24 23:06:33 EDT 2025
Tue Jul 01 01:05:33 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c445t-abb303c1c3363ab74ebc01cc0a880d2654bde95e7fcd39e4d5a06a933df64dca3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.nature.com/articles/npp2016265.pdf
PMID 27882998
PQID 1877395203
PQPubID 33935
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5357051
proquest_miscellaneous_1881760184
proquest_miscellaneous_1843967783
proquest_journals_1877395203
pubmed_primary_27882998
crossref_primary_10_1038_npp_2016_265
crossref_citationtrail_10_1038_npp_2016_265
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-04-01
PublicationDateYYYYMMDD 2017-04-01
PublicationDate_xml – month: 04
  year: 2017
  text: 2017-04-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: New York
PublicationTitle Neuropsychopharmacology (New York, N.Y.)
PublicationTitleAlternate Neuropsychopharmacology
PublicationYear 2017
Publisher Nature Publishing Group
Publisher_xml – name: Nature Publishing Group
References YH Yau (BFnpp2016265_CR49) 2015; 23
SL McElroy (BFnpp2016265_CR36) 2015; 72
JC Wu (BFnpp2016265_CR48) 1997; 17
V Voon (BFnpp2016265_CR44) 2015; 20
MA Bloomfield (BFnpp2016265_CR5) 2014; 39
HW de Jong (BFnpp2016265_CR11) 2007; 52
H Ziauddeen (BFnpp2016265_CR50) 2013; 18
JE Grant (BFnpp2016265_CR17) 2010; 197
RN Gunn (BFnpp2016265_CR20) 1997; 6
T Toneatto (BFnpp2016265_CR42) 2009; 18
VC Cambridge (BFnpp2016265_CR9) 2013; 73
JE Grant (BFnpp2016265_CR18) 2006; 163
SH Keller (BFnpp2016265_CR26) 2012; 53
ND Volkow (BFnpp2016265_CR43) 2014; 19
D Weintraub (BFnpp2016265_CR46) 2010; 67
RS Desikan (BFnpp2016265_CR12) 2006; 31
C Blanco (BFnpp2016265_CR4) 2015; 110
HK Karlsson (BFnpp2016265_CR25) 2015; 21
A Badiani (BFnpp2016265_CR2) 2011; 12
C Giuliano (BFnpp2016265_CR15) 2015; 20
J Hirvonen (BFnpp2016265_CR23) 2009; 36
RP Woods (BFnpp2016265_CR47) 1998; 22
J Joutsa (BFnpp2016265_CR24) 2012; 60
GJ Wang (BFnpp2016265_CR45) 2011; 19
J Linnet (BFnpp2016265_CR34) 2012; 204
S Forsback (BFnpp2016265_CR14) 2009; 52
T Kienast (BFnpp2016265_CR29) 2013; 46
CS Patlak (BFnpp2016265_CR38) 1985; 5
Y Li (BFnpp2016265_CR33) 2008; 28
I Boileau (BFnpp2016265_CR6) 2013; 108
SW Kim (BFnpp2016265_CR30) 2001; 49
SN Haber (BFnpp2016265_CR21) 2010; 35
TW Robbins (BFnpp2016265_CR40) 2015; 30
KA Brownley (BFnpp2016265_CR8) 2016; 165
I Boileau (BFnpp2016265_CR7) 2014; 19
JE Grant (BFnpp2016265_CR19) 2010; 36
RC Kessler (BFnpp2016265_CR27) 2013; 73
L Kovanen (BFnpp2016265_CR31) 2016; 22
I Mick (BFnpp2016265_CR37) 2015; 41
B Fischl (BFnpp2016265_CR13) 2002; 33
SL McElroy (BFnpp2016265_CR35) 2013; 46
C Li (BFnpp2016265_CR32) 2016; 41
K Alakurtti (BFnpp2016265_CR1) 2015; 35
A Heinz (BFnpp2016265_CR22) 2005; 62
L Clark (BFnpp2016265_CR10) 2012; 63
RC Kessler (BFnpp2016265_CR28) 2008; 38
KC Berridge (BFnpp2016265_CR3) 2009; 9
MN Potenza (BFnpp2016265_CR39) 2005; 62
JK Zubieta (BFnpp2016265_CR51) 1996; 2
JE Grant (BFnpp2016265_CR16) 2008; 69
BFnpp2016265_CR41
References_xml – volume: 49
  start-page: 914
  year: 2001
  ident: BFnpp2016265_CR30
  publication-title: Biol Psychiatry
  doi: 10.1016/S0006-3223(01)01079-4
– volume: 19
  start-page: 1037
  year: 2014
  ident: BFnpp2016265_CR43
  publication-title: Mol Psychiatry
  doi: 10.1038/mp.2014.58
– volume: 52
  start-page: 1505
  year: 2007
  ident: BFnpp2016265_CR11
  publication-title: Phys Med Biol
  doi: 10.1088/0031-9155/52/5/019
– volume: 21
  start-page: 1057
  year: 2015
  ident: BFnpp2016265_CR25
  publication-title: Mol Psychiatry
  doi: 10.1038/mp.2015.153
– volume: 20
  start-page: 566
  year: 2015
  ident: BFnpp2016265_CR44
  publication-title: CNS Spectr
  doi: 10.1017/S1092852915000681
– volume: 6
  start-page: 279
  year: 1997
  ident: BFnpp2016265_CR20
  publication-title: Neuroimage
  doi: 10.1006/nimg.1997.0303
– volume: 41
  start-page: 1742
  year: 2015
  ident: BFnpp2016265_CR37
  publication-title: Neuropsychopharmacology
  doi: 10.1038/npp.2015.340
– volume: 20
  start-page: 537
  year: 2015
  ident: BFnpp2016265_CR15
  publication-title: CNS Spectr
  doi: 10.1017/S1092852915000668
– volume: 5
  start-page: 584
  year: 1985
  ident: BFnpp2016265_CR38
  publication-title: J Cereb Blood Flow Metab
  doi: 10.1038/jcbfm.1985.87
– volume: 28
  start-page: 2814
  year: 2008
  ident: BFnpp2016265_CR33
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.5447-07.2008
– volume: 39
  start-page: 2397
  year: 2014
  ident: BFnpp2016265_CR5
  publication-title: Neuropsychopharmacology
  doi: 10.1038/npp.2014.87
– volume: 69
  start-page: 783
  year: 2008
  ident: BFnpp2016265_CR16
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v69n0511
– volume: 36
  start-page: 233
  year: 2010
  ident: BFnpp2016265_CR19
  publication-title: Am J Drug Alcohol Abuse
  doi: 10.3109/00952990.2010.491884
– volume: 22
  start-page: 139
  year: 1998
  ident: BFnpp2016265_CR47
  publication-title: J Comput Assist Tomogr
  doi: 10.1097/00004728-199801000-00027
– volume: 17
  start-page: 402
  year: 1997
  ident: BFnpp2016265_CR48
  publication-title: Neuropsychopharmacology
  doi: 10.1016/S0893-133X(97)00089-4
– volume: 73
  start-page: 904
  year: 2013
  ident: BFnpp2016265_CR27
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2012.11.020
– ident: BFnpp2016265_CR41
  doi: 10.1002/14651858.CD001867.pub3
– volume: 62
  start-page: 1015
  year: 2005
  ident: BFnpp2016265_CR39
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archpsyc.62.9.1015
– volume: 108
  start-page: 953
  year: 2013
  ident: BFnpp2016265_CR6
  publication-title: Addiction
  doi: 10.1111/add.12066
– volume: 62
  start-page: 57
  year: 2005
  ident: BFnpp2016265_CR22
  publication-title: Arch General Psychiatry
  doi: 10.1001/archpsyc.62.1.57
– volume: 9
  start-page: 65
  year: 2009
  ident: BFnpp2016265_CR3
  publication-title: Curr Opin Pharmacol
  doi: 10.1016/j.coph.2008.12.014
– volume: 30
  start-page: 66
  year: 2015
  ident: BFnpp2016265_CR40
  publication-title: Curr Opin Neurobiol
  doi: 10.1016/j.conb.2014.09.005
– volume: 19
  start-page: 1601
  year: 2011
  ident: BFnpp2016265_CR45
  publication-title: Obesity
  doi: 10.1038/oby.2011.27
– volume: 19
  start-page: 1305
  year: 2014
  ident: BFnpp2016265_CR7
  publication-title: Mol Psychiatry
  doi: 10.1038/mp.2013.163
– volume: 41
  start-page: 2122
  year: 2016
  ident: BFnpp2016265_CR32
  publication-title: Neuropsychopharmacology
  doi: 10.1038/npp.2016.12
– volume: 73
  start-page: 887
  year: 2013
  ident: BFnpp2016265_CR9
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2012.10.022
– volume: 46
  start-page: 130
  year: 2013
  ident: BFnpp2016265_CR29
  publication-title: Pharmacopsychiatry
  doi: 10.1055/s-0032-1331747
– volume: 72
  start-page: 235
  year: 2015
  ident: BFnpp2016265_CR36
  publication-title: JAMA Psychiatry
  doi: 10.1001/jamapsychiatry.2014.2162
– volume: 38
  start-page: 1351
  year: 2008
  ident: BFnpp2016265_CR28
  publication-title: Psychol Med
  doi: 10.1017/S0033291708002900
– volume: 2
  start-page: 1225
  year: 1996
  ident: BFnpp2016265_CR51
  publication-title: NatMed
– volume: 33
  start-page: 341
  year: 2002
  ident: BFnpp2016265_CR13
  publication-title: Neuron
  doi: 10.1016/S0896-6273(02)00569-X
– volume: 18
  start-page: 1287
  year: 2013
  ident: BFnpp2016265_CR50
  publication-title: Mol Psychiatry
  doi: 10.1038/mp.2012.154
– volume: 36
  start-page: 275
  year: 2009
  ident: BFnpp2016265_CR23
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-008-0935-6
– volume: 23
  start-page: 134
  year: 2015
  ident: BFnpp2016265_CR49
  publication-title: Harv Rev Psychiatry
  doi: 10.1097/HRP.0000000000000051
– volume: 52
  start-page: 286
  year: 2009
  ident: BFnpp2016265_CR14
  publication-title: J Labelled Combd Rad
  doi: 10.1002/jlcr.1599
– volume: 35
  start-page: 4
  year: 2010
  ident: BFnpp2016265_CR21
  publication-title: Neuropsychopharmacology
  doi: 10.1038/npp.2009.129
– volume: 60
  start-page: 1992
  year: 2012
  ident: BFnpp2016265_CR24
  publication-title: Neuroimage
  doi: 10.1016/j.neuroimage.2012.02.006
– volume: 18
  start-page: 219
  year: 2009
  ident: BFnpp2016265_CR42
  publication-title: Am J Addict
  doi: 10.1080/10550490902787007
– volume: 35
  start-page: 1199
  year: 2015
  ident: BFnpp2016265_CR1
  publication-title: J Cereb Blood Flow Metab
  doi: 10.1038/jcbfm.2015.53
– volume: 53
  start-page: 495
  year: 2012
  ident: BFnpp2016265_CR26
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.111.095240
– volume: 63
  start-page: 40
  year: 2012
  ident: BFnpp2016265_CR10
  publication-title: Neuroimage
  doi: 10.1016/j.neuroimage.2012.06.067
– volume: 165
  start-page: 409
  year: 2016
  ident: BFnpp2016265_CR8
  publication-title: Ann Intern Med
  doi: 10.7326/M15-2455
– volume: 110
  start-page: 1340
  year: 2015
  ident: BFnpp2016265_CR4
  publication-title: Addiction
  doi: 10.1111/add.12946
– volume: 163
  start-page: 303
  year: 2006
  ident: BFnpp2016265_CR18
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.163.2.303
– volume: 31
  start-page: 968
  year: 2006
  ident: BFnpp2016265_CR12
  publication-title: Neuroimage
  doi: 10.1016/j.neuroimage.2006.01.021
– volume: 22
  start-page: 70
  year: 2016
  ident: BFnpp2016265_CR31
  publication-title: Eur Addict Res
  doi: 10.1159/000435876
– volume: 67
  start-page: 589
  year: 2010
  ident: BFnpp2016265_CR46
  publication-title: Arch Neurol
  doi: 10.1001/archneurol.2010.65
– volume: 46
  start-page: 239
  year: 2013
  ident: BFnpp2016265_CR35
  publication-title: Int J Eating Disord
  doi: 10.1002/eat.22114
– volume: 12
  start-page: 685
  year: 2011
  ident: BFnpp2016265_CR2
  publication-title: Nat Rev Neurosci
  doi: 10.1038/nrn3104
– volume: 204
  start-page: 55
  year: 2012
  ident: BFnpp2016265_CR34
  publication-title: Psychiatry Res
  doi: 10.1016/j.pscychresns.2012.04.012
– volume: 197
  start-page: 330
  year: 2010
  ident: BFnpp2016265_CR17
  publication-title: Br J Psychiatry
  doi: 10.1192/bjp.bp.110.078105
SSID ssj0015768
Score 2.483937
Snippet Although behavioral addictions share many clinical features with drug addictions, they show strikingly large variation in their behavioral phenotypes (such as...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1169
SubjectTerms Adult
Analgesics, Opioid - administration & dosage
Analgesics, Opioid - metabolism
Behavior, Addictive - diagnostic imaging
Behavior, Addictive - metabolism
Binge eating
Brain - diagnostic imaging
Brain - metabolism
Bulimia - diagnostic imaging
Bulimia - metabolism
Carbon Radioisotopes
Dihydroxyphenylalanine - administration & dosage
Dihydroxyphenylalanine - analogs & derivatives
Dopamine - metabolism
Female
Fentanyl - administration & dosage
Fentanyl - analogs & derivatives
Gambling - diagnostic imaging
Gambling - metabolism
Humans
Male
Middle Aged
Original
Positron-Emission Tomography
Radiopharmaceuticals
Title Dopamine and Opioid Neurotransmission in Behavioral Addictions: A Comparative PET Study in Pathological Gambling and Binge Eating
URI https://www.ncbi.nlm.nih.gov/pubmed/27882998
https://www.proquest.com/docview/1877395203
https://www.proquest.com/docview/1843967783
https://www.proquest.com/docview/1881760184
https://pubmed.ncbi.nlm.nih.gov/PMC5357051
Volume 42
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9NADLZgkxAvCDpggTEdEuyFhSW5yyXhBbWjY0LaqFAn9S26XxWRaFpo9tBH_nPsa5puIPYcnxLFd7Y_2_cZ4I1JeGqzSIeCkI5wiQxzE_NQWlmYvJCFUwQULy7l-ZX4MkknbcJt2bZVbmyiN9R2bihHfhLnGdWUkoh_XPwMaWoUVVfbERr3YZeoy6ilK5t0gCumWNpHkQUPEYtN2sb3iOcn9YLIKmP5PiG3ctMl_RNn_t0uecP_nD2GR23gyPprTT-Be67uwV6_RtA8W7Ej5ls5fY68Bw8u2op5D45Ga27q1TEbb69aLY_9io61erUHvz8hfJ7hGqZqy74uqnllmafuaMid4XagvBqrajbobvazvrWVvxix_MD67HTLJM5GwzGjHsUVrRippjOy7LOaaboD798zoKwiGypqvn4KV2fD8el52M5nCI0QaRMqrdEBmthwLrnSmXDaRLExkUKjYPHHCm1dkbpsaiwvnLCpiqQqOLdTKaxR_Bns1PPa7QNDlINIM9KRckbYOFJWpTnNtrQ8s6mYBvBuo6LStOTlNEPjR-mL6DwvUaElKbTE9wbwtpNerEk7_iN3sNF22R7dZbndaAG87h7jX6ZKiqrd_JpkMI4j6r07ZfKYGo5yEcDz9QbqPibJENgg0A0gu7W1OgEi_b79pK6-e_LvlKcZGtIXd3_6S3iYUPzhW4wOYKf5de1eYfTU6EN_RA5hdzC8HH37Aw_yHZs
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTgJeEHR8FAYYie2FhSWx84WEULt1dGwt1dRJfQuO7YpKNC20E8oj_xB_I3dumm4g9rZnnxMrdznfz3f-HcBr5fNAR27mCEI6wvihEyuPO6EOExUnYWIkAcVuL-yci0_DYLgBv1d3YaiscuUTraPWU0Vn5PteHFFOyXf5h9l3h7pGUXZ11UJjaRYnpviJkG3-_vgQ9bvj-0ftwUHHKbsKOEqIYOHILEO3rTzFechlFgmTKddTypVoytoPA5FpkwQmGinNEyN0IN1QIu7Xo1BoJTk-9xZsCo5QpgabrXavf1blLSh6t3Frwh1Ef8Oy1N7l8X4-I3pML3zr00Z2eRP8J7L9u0Dz0o53dB_ulaEqay5t6wFsmLwOW80cYfqkYLvMFo_aU_k63O6WOfo67PaXbNjFHhusL3fN9-yMiie72IJfhwjYJziHyVyzz7PxdKyZJQtZ0AaKBkgneWycs1bFJcCaWo_tVYz5O9ZkB2vuctZvDxhVRRY0oy8XlVtnH-Uko1v39j0tOsdkbUnl3g_h_EZ09whq-TQ3T4AhrkJs62auNEpoz5VaBjF109Q80oEYNeDNSkWpKunSqWvHt9Sm7XmcokJTUmiK723ATiU9W9KE_Edue6XttHQW83Rt2g14VQ3jV6bcjczN9IJkMHIksr9rZWKPSpxi0YDHSwOqFuNHCKUQWjcgumJalQDRjF8dycdfLd14wIMIXffT65f-Eu50Bt3T9PS4d_IM7voU_dgCp22oLX5cmOcYuy2yF-UPw-DLTf-jfwCVu1wQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NIU28IOj4CAwwEtsLC01iOx9ICHVry8bY6EMn9S04tisq0bTQTqiP_Fv8ddy5abqB2Nuec46j3Pl8P9_5dwCvdMSlSYLCF4R0hI1iP9Uh92MTZzrN4swqAoqnZ_HRufg4kIMN-L26C0NllSuf6By1mWg6I2-GaUI5pSjgzWFVFtFrd99Pv_vUQYoyrat2GksTObGLnwjfZu-O26jr3SjqdvqHR37VYcDXQsi5r4oCXbgONecxV0UibKGDUOtAoVmbKJaiMDaTNhlqwzMrjFRBrDLOzTAWRiuO770FtxMuQ1pjyaAGeyHF8S6CzbiPOHBQFd0HPG2WUyLKDOM3EW1pl7fDf2Lcv0s1L-193XtwtwpaWWtpZfdhw5YN2G6VCNjHC7bHXBmpO59vwNZpla1vwF5vyYu92Gf99TWv2b4bUTNmL7bhVxuh-xjHMFUa9nk6mowMc7Qhc9pK0RTpTI-NSnZQswqwljEjdylj9pa12OGaxZz1On1G9ZELGtFT89rBsw9qXND9ezfPAZ1oso6iwu8HcH4jmnsIm-WktI-BIcJClBsUgbJamDBQRsmU-moanhgphh68Xqko1xVxOvXv-Ja7BD5Pc1RoTgrNcV4Pdmvp6ZIw5D9yOytt55XbmOVrI_fgZf0Y_zJlcVRpJxckgzEk0f5dK5OGVOyUCg8eLQ2o_pgoQVCFINuD5Ipp1QJEOH71STn66ojHJZcJOvEn13_6C9jClZl_Oj47eQp3IgqDXKXTDmzOf1zYZxjEzYvnbrUw-HLTy_MPpAte4A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dopamine+and+Opioid+Neurotransmission+in+Behavioral+Addictions%3A+A+Comparative+PET+Study+in+Pathological+Gambling+and+Binge+Eating&rft.jtitle=Neuropsychopharmacology+%28New+York%2C+N.Y.%29&rft.au=Majuri%2C+Joonas&rft.au=Joutsa%2C+Juho&rft.au=Johansson%2C+Jarkko&rft.au=Voon%2C+Valerie&rft.date=2017-04-01&rft.pub=Nature+Publishing+Group&rft.issn=0893-133X&rft.eissn=1740-634X&rft.volume=42&rft.issue=5&rft.spage=1169&rft_id=info:doi/10.1038%2Fnpp.2016.265&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=4320726611
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0893-133X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0893-133X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0893-133X&client=summon